The administrative hearing on broader marijuana rescheduling from Schedule I to Schedule III under the Controlled Substances Act began June 29, 2026, and was scheduled to conclude by July 15. This followed a December 2025 executive order directing expedited review and an April 2026 final order that immediately moved FDA-approved and state-licensed medical cannabis products to Schedule III. The process now shifts to an administrative law judge recommendation, potential further agency review, and a final rule. Traders price low odds of completion before late 2026 due to procedural timelines, participant challenges, and the need for formal publication, while monitoring any interim announcements or delays that could shift resolution into 2027.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$796,424 ปริมาณ
Mar 31, 2026
September 30
22%
December 31
27%
$796,424 ปริมาณ
September 30
$0 ปริมาณ
22%
December 31
$186,853 ปริมาณ
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The administrative hearing on broader marijuana rescheduling from Schedule I to Schedule III under the Controlled Substances Act began June 29, 2026, and was scheduled to conclude by July 15. This followed a December 2025 executive order directing expedited review and an April 2026 final order that immediately moved FDA-approved and state-licensed medical cannabis products to Schedule III. The process now shifts to an administrative law judge recommendation, potential further agency review, and a final rule. Traders price low odds of completion before late 2026 due to procedural timelines, participant challenges, and the need for formal publication, while monitoring any interim announcements or delays that could shift resolution into 2027.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Feb 7, 2026, 5:04 PM ET
ปริมาณการซื้อขาย
$796,424วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The administrative hearing on broader marijuana rescheduling from Schedule I to Schedule III under the Controlled Substances Act began June 29, 2026, and was scheduled to conclude by July 15. This followed a December 2025 executive order directing expedited review and an April 2026 final order that immediately moved FDA-approved and state-licensed medical cannabis products to Schedule III. The process now shifts to an administrative law judge recommendation, potential further agency review, and a final rule. Traders price low odds of completion before late 2026 due to procedural timelines, participant challenges, and the need for formal publication, while monitoring any interim announcements or delays that could shift resolution into 2027.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$796,424วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The administrative hearing on broader marijuana rescheduling from Schedule I to Schedule III under the Controlled Substances Act began June 29, 2026, and was scheduled to conclude by July 15. This followed a December 2025 executive order directing expedited review and an April 2026 final order that immediately moved FDA-approved and state-licensed medical cannabis products to Schedule III. The process now shifts to an administrative law judge recommendation, potential further agency review, and a final rule. Traders price low odds of completion before late 2026 due to procedural timelines, participant challenges, and the need for formal publication, while monitoring any interim announcements or delays that could shift resolution into 2027.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย